Cohance Lifesciences Ltd (COHANCE)
₹444.30
Mkt cap
₹16,999 Cr
P/E ratio
158.00
P/B
4.36
Div yield
0.00%
ROE
4.89%
ROCE
5.81%
EPS (TTM)
₹2.81
Book value
₹102
52W range
267–893
Sector
Healthcare
Price history
Previous close
Cohance Lifesciences is a Hyderabad-based CDMO operating across pharmaceutical development, manufacturing, APIs, formulations and specialty chemicals. The company states that it features among the Top 20 CDMOs globally; its Pharma CDMO business works with 19 of the top 20 global innovators, while the API portfolio ranks among the top three suppliers in 8 of its top 10 molecules. [1] [2]
NSE COHANCEBSE 543064
Health check
Cautious
ValuationExpensive
ProfitabilityWeak
GrowthHigh
TechnicalsNeutral
52-week range
−50.24% from high₹444
₹267+66.59% from low₹893
Current
₹444.30
Prev close
₹481.35
Day
−7.70%
Price performance
1D
−7.70%
1W
−1.23%
1M
−2.97%
3M
+4.47%
6M
−4.97%
1Y
−49.89%
YTD
−14.28%
Financials
Revenue, profit & margin
P/E ratio
158.0×
COHANCE is 359% above the sector median of 34.4×
COHANCE158.0×
Sector median34.4×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 348 | 231 | 220 | 253 | 488 | 604 | 676 | 840 | 549 | 556 | 545 | 619 | 422 | |
| Expenses | 181 | 133 | 154 | 180 | 363 | 398 | 439 | 611 | 437 | 435 | 449 | 520 | 421 | |
| Operating Profit | 167 | 98 | 66 | 73 | 125 | 205 | 237 | 229 | 112 | 121 | 95 | 99 | 1 | |
| OPM % | 48% | 42% | 30% | 29% | 26% | 34% | 35% | 27% | 20% | 22% | 18% | 16% | 0.3% | |
| Other Income | 11 | 20 | 14 | 17 | 19 | 16 | 22 | -4 | 6 | 16 | 1 | -18 | 12 | |
| Interest | 1 | 0 | 2 | 2 | 10 | 10 | 11 | 10 | 10 | 9 | 9 | 9 | 7 | |
| Depreciation | 13 | 12 | 13 | 17 | 31 | 38 | 44 | 54 | 45 | 44 | 47 | 51 | 50 | |
| Profit before tax | 164 | 105 | 65 | 71 | 103 | 174 | 205 | 161 | 63 | 84 | 41 | 20 | -43 | |
| Tax % | 26% | 25% | 29% | 25% | 27% | 21% | 25% | 27% | 26% | 21% | 29% | 58% | 5% | |
| Net Profit | 121 | 80 | 47 | 53 | 75 | 138 | 153 | 117 | 46 | 66 | 29 | 8 | -45 | |
| EPS in Rs | 4.74 | 3.13 | 1.84 | 2.10 | 2.96 | 5.44 | 6.01 | 4.73 | 1.28 | 1.94 | 0.96 | 0.51 | -0.63 | |
| Raw PDF |
Earnings
Results dates & reactionsNext results
6 Nov '26
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.79% · closed higher next day 10 of last 23
| Q1FY24 | Q2FY24 | Q3FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26† | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 8 Aug '23◦ | 10 Nov '23◦ | 6 Feb '24◦ | 9 Aug '24◦ | 13 Nov '24◦ | 13 Feb '25◦ | 28 May '25◦ | 13 Aug '25◦ | 12 Nov '25 | 12 Feb '26◦ | 12 May '26◦ | 5 Aug '26◦ |
| Earnings day | +0.59% | −0.47% | +1.16% | +4.69% | +0.98% | −2.71% | −3.81% | −7.32% | −8.81% | −10.02% | −5.85% | +2.20% |
| +1 day | +2.59% | −1.81% | +3.32% | +3.52% | +1.48% | −0.06% | −5.51% | −9.00% | −10.78% | −12.59% | −8.14% | +3.80% |
| +5 days | +6.38% | +3.33% | +6.68% | +0.19% | +2.50% | +9.50% | −4.07% | −10.28% | −15.66% | −12.93% | −13.31% | +3.43% |
| +15 days | +4.72% | +14.74% | +4.63% | +12.58% | +3.46% | +3.26% | −10.65% | +2.73% | −20.41% | −19.44% | −12.25% | +5.72% |
| +30 days | +8.23% | +20.23% | +2.71% | +21.96% | −9.79% | −2.27% | −10.18% | −11.12% | −22.11% | −11.06% | −5.49% | +1.99% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Shareholding
as of Sep 202657.48%Promoter
Promoters57.48%0.01
FIIs7.71%1.21
DIIs18.86%1.23
Public15.95%0.03
Government0.00%0.01
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,777.70 | 34.66 | 4,26,530 | 0.90% | 1,995 | −10.53% | 16,199 | +11.88% | 20.53% |
| Divi's Lab. | ₹9,780.00 | 87.14 | 2,59,628 | 0.31% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| Torrent Pharma. | ₹4,613.40 | 80.83 | 1,75,479 | 0.82% | 534 | −10.03% | 4,979 | +50.79% | 15.19% |
| Laurus Labs | ₹2,405.50 | 97.00 | 1,29,972 | 0.08% | 436 | +126.43% | 2,206 | +33.44% | 17.76% |
| Zydus Lifesci. | ₹1,245.50 | 25.52 | 1,24,239 | 0.08% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| Dr Reddy's Labs | ₹1,352.00 | 40.30 | 1,12,849 | 0.59% | 913 | −31.35% | 8,698 | −1.48% | 13.04% |
| Cipla | ₹1,378.90 | 35.87 | 1,11,397 | 0.94% | 852 | −35.05% | 7,404 | −2.44% | 15.49% |
| Cohance Life | ₹444.30 | 157.88 | 16,999 | 0.00% | −45 | −144.15% | 422 | −23.13% | 5.81% |
| Median: 158 Co. | ₹426.38 | 34.39 | 1,921 | 0.08% | 14 | +22.08% | 175 | +18.92% | 15.12% |
Filings
Annual reports7
Concall transcripts67
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025TranscriptNov 2025TranscriptAug 2025PPTAug 2025TranscriptJun 2025PPTJun 2025RECJun 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025PPTJan 2025TranscriptDec 2024PPTDec 2024TranscriptDec 2024
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 27 Oct - Q2 and H1FY27 results conference call scheduled for 6 November 2026 at 6:30 P.M. IST.Board Meeting Intimation for Considering The Unaudited Financial Results (Standalone And Consolidated) Of The Company, For The Quarter And Half Year Ended 30 September 2026 26 Oct - Board meets on 6 November 2026 to approve Q2 and half-year 2026 unaudited results.General Updates 12 Oct - MCA approved appointment of Umang Vohra as Chairman and Group CEO on 8 October 2026.Grant Of Stock Options To Certain Eligible Employees Of The Company 9 Oct - Nomination committee approved 2,60,194 ESOP 2026 and 6,14,594 ESOP 2023 options on 9 October 2026.Announcement under Regulation 30 (LODR)-Change in Management 9 Oct - Abhimanyu Ojha appointed CFO and KMP effective 12 October 2026.